BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 16924652)

  • 1. Refractory thrombocytopenia and positive platelet crossmatches without HLA or platelet-specific antibodies.
    Kankirawatana S; Huang ST; Arndt DW; Marques MB
    Am J Hematol; 2007 Feb; 82(2):175-6. PubMed ID: 16924652
    [No Abstract]   [Full Text] [Related]  

  • 2. Platelet transfusions to HLA-immunized recipients: how to be or not to be matched.
    Rubinstein P
    Transfusion; 2010 Nov; 50(11):2292-4. PubMed ID: 21182628
    [No Abstract]   [Full Text] [Related]  

  • 3. Platelet replacement therapy: a clinical assessment.
    Hester JP; McCredie KB; Freireich EJ
    Prog Clin Biol Res; 1978; 28():281-93. PubMed ID: 752154
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of HLA-C matching in histocompatible platelet transfusion therapy of alloimmunized thrombocytopenic patients.
    Duquesnoy RJ; Filip DJ; Tomasulo PA; Aster RH
    Transplant Proc; 1977 Dec; 9(4):1827-8. PubMed ID: 601843
    [No Abstract]   [Full Text] [Related]  

  • 5. Validation of HLAMatchmaker algorithm in identifying acceptable HLA mismatches for thrombocytopenic patients refractory to platelet transfusions.
    Brooks EG; MacPherson BR; Fung MK
    Transfusion; 2008 Oct; 48(10):2159-66. PubMed ID: 18631168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of crossmatch outcome of highly sensitized patients by single and/or multiple antigen bead luminex assay.
    Vaidya S; Partlow D; Susskind B; Noor M; Barnes T; Gugliuzza K
    Transplantation; 2006 Dec; 82(11):1524-8. PubMed ID: 17164726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor availability for platelet transfusion support of alloimmunized thrombocytopenic patients.
    Duquesnoy RJ; Vieira J; Aster RH
    Transplant Proc; 1977 Mar; 9(1):519-21. PubMed ID: 867500
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of patients refractory to platelet transfusion.
    Chockalingam P; Sacher RA
    J Infus Nurs; 2007; 30(4):220-5. PubMed ID: 17667077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Optimal donor selection and the effectiveness of platelet transfusion in cases refractory to platelet transfusion].
    Iwanaga T; Tsubaki K; Horiuchi A; Fujikawa Y; Kanemitsu Y
    Rinsho Ketsueki; 1986 Jul; 27(7):1274-7. PubMed ID: 3784009
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical aspects of platelet transfusion].
    Julia A; Massuet L; Pujol M; Martín Vega C
    Sangre (Barc); 1985; 30(4-B):548-56. PubMed ID: 3909466
    [No Abstract]   [Full Text] [Related]  

  • 12. Platelet transfusion refractoriness.
    Hod E; Schwartz J
    Br J Haematol; 2008 Jul; 142(3):348-60. PubMed ID: 18510692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Serological typing of HLA].
    Kuwata S
    Nihon Rinsho; 2005 Jul; 63 Suppl 7():738-44. PubMed ID: 16111384
    [No Abstract]   [Full Text] [Related]  

  • 14. Luminex donor-specific crossmatches.
    Billen EV; Voorter CE; Christiaans MH; van den Berg-Loonen EM
    Tissue Antigens; 2008 Jun; 71(6):507-13. PubMed ID: 18380779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants.
    Bray RA; Hurley CK; Kamani NR; Woolfrey A; Müller C; Spellman S; Setterholm M; Confer DL
    Biol Blood Marrow Transplant; 2008 Sep; 14(9 Suppl):45-53. PubMed ID: 18721780
    [No Abstract]   [Full Text] [Related]  

  • 16. Advances in the selection of HLA-compatible donors: refinements in HLA typing and matching over the first 20 years of the National Marrow Donor Program Registry.
    Spellman S; Setterholm M; Maiers M; Noreen H; Oudshoorn M; Fernandez-Viña M; Petersdorf E; Bray R; Hartzman RJ; Ng J; Hurley CK
    Biol Blood Marrow Transplant; 2008 Sep; 14(9 Suppl):37-44. PubMed ID: 18721779
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of HLA in hematopoietic SCT.
    Nowak J
    Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S71-6. PubMed ID: 18978750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for new donor typing based on donor HLA type or donor characteristics.
    Little AM; Jindra P; Raffoux C
    Tissue Antigens; 2007 Apr; 69 Suppl 1():8-9. PubMed ID: 17445153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Blood component transfusion therapy].
    Takahashi K; Juji T
    Nihon Naika Gakkai Zasshi; 1991 Jun; 80(6):897-901. PubMed ID: 1919204
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical relevance of Luminex donor-specific crossmatches: data from 165 renal transplants.
    Billen EV; Christiaans MH; van den Berg-Loonen EM
    Tissue Antigens; 2009 Sep; 74(3):205-12. PubMed ID: 19497037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.